Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026: Report Identifies Over 140 Organizations - Research and Markets

This image opens in the lightbox

News provided by

Research and Markets

10 Nov, 2016, 12:29 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, Nov 10, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026" report to their offering.

The "Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026" report provides an extensive study of the rapidly growing market of gene therapy vectors, with a special focus on lentivirus, AAV, adenovirus, retrovirus and plasmid DNA.

Gene therapies require a viral or non-viral vector to efficiently transfer the therapeutic gene into targets cells. It is well known that the gene therapy market is characterized by a robust pipeline of drugs targeting several therapeutic indications. The pipeline is witnessing continuous progression that has further led to an upward surge in demand for gene delivery tools, including both viral and non-viral vectors.

Several players, including pharmaceutical companies, research institutes, contract manufacturing organizations and non-profit organizations, are playing a critical role in the development and production of these vectors. Led by technological advancements, these organizations have developed and introduced proprietary platforms to overcome the challenges posed by conventional production technologies and have also made heavy investments in the expansion of their existing capabilities for vector production.

During the course of our study, we identified over 140 organizations that are actively involved in the production of viral vectors and plasmid DNA.

In addition to other elements, the study provides information on:

- The current status of the market with respect to key players along with information on the location of their manufacturing facilities, scale of production, type of vectors manufactured, purpose of production (fulfilling in-house requirement/as a contract service provider) and the type of organization (industry/academia).

- Most active regions in terms of vector manufacturing; the report contains schematic representations of world maps that clearly indicate the locations of global vector manufacturing hubs.

- Elaborate profiles of key players that have commercial scale production capabilities for viral vector/plasmid DNA; each profile covers an overview of the company, its financial performance, information on its manufacturing facilities, vector manufacturing technology, recent investments, expansions and collaborations.

- A discussion on the key enablers of the market and challenges associated with the vector production process.

- Potential future growth of the vector manufacturing market segmented by the type of vector and phase of development. For the purposes of our analysis, we took into consideration several parameters that are likely to impact the growth of this market over the next decade; these include the likely increase in the number of clinical studies, increase in the patient population, existing price variations among different vector types, estimated dosage frequency and the anticipated success of commercial gene therapy products.

Key Topics Covered:

1. Preface

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

2. Executive Summary

3. Introduction

3.1. Chapter Overview

3.2. Viral Vectors

3.3. Types of Viral Vectors

3.4. Non-Viral Vectors

3.5. Applications of Viral and Non-Viral Vectors

3.6. Current State of Gene Therapy Market

4. Market Overview

4.1. Chapter Overview

4.2. Viral Vectors and Plasmid DNA Manufacturers: Overall Market Landscape

4.3. Viral Vector Manufacturing

4.4. Plasmid DNA Manufacturing

4.5. Key Insights on the Overall Vector Manufacturing Market

5. Viral Vectors

5.1. Chapter Overview

5.2. BioReliance (A Part of SAFC Commercial)

5.3. Biovian

5.4. Brammer Bio

5.5. Cell and Gene Therapy Catapult

5.6. Cobra Biologics

5.7. FinVector

5.8. FUJIFILM Diosynth Biotechnologies

5.9. Lonza

5.10. MassBiologics

5.11. MolMed

5.12. Oxford BioMedica

5.13. Sanofi (CEPiA, Sanofi Pasteur, Genzyme)

5.14. Spark Therapeutics

5.15. uniQure

5.16. ViGene Biosciences

5.17. Wuxi AppTec

5.18. Drivers and Challenges

6. Plasmid DNA

6.1. Chapter Overview

6.2. Aldevron

6.3. Eurogentec

6.4. Richter-Helm

6.5. Drivers and Challenges

7. Opportunity Analysis

7.1. Chapter Overview

7.2. Scope of the Forecast

7.3. Forecast Methodology

7.4. Input Data Tables and Assumptions

7.5. Vector Manufacturing Market Outlook, 2016-2026

7.5.2. Distribution by Phase of Development

8. Survey Analysis

8.1. Chapter Overview

8.2. Seniority Level of Respondents

8.3. Type of Vector

8.4. Scale of Production

8.5. Vector Stabilization Technology

8.6. In-house v/s Contract Service Production

9. Conclusion

9.1. Accelerated Progression in the Pipeline of Gene Therapy Drugs Will Continue to Act as a Key Driver of the Vector Manufacturing Market

9.2. In Light of Exorbitant Costs Associated with Developing In-house Facilities, Outsourcing has Emerged as a Convenient Alternative

9.3. Both Industry and Academia are Leading the Manufacturing Efforts

9.4. Innovative Technological Platforms have Emerged as Vital Enablers

9.5. Partnerships/Collaborations will Further Contribute to the Rapid Development of This Market

9.6. Anticipated Market Success Backed up by Progressive Pipeline and Rapid Development

10. Interview Transcripts

10.1. Chapter Overview

10.2. Alain Lamproye, President of Biopharma Business Unit, Novasep

10.3. Bakhos A Tannous, Director, Massachusetts General Hospital (MGH) Viral Vector Development Facility

10.4. Brian M Dattilo, Business Development Manager, Waisman Biomanufacturing

10.5. Joost van den Berg, Director, Amsterdam BioTherapeutics Unit (AmBTU)

10.6. Nicole Faust, Chief Scientific Officer, Cevec

10.7. Semyon Rubinchik, Scientific Director, ACGT

11. Appendix 1: Tabulated Data

12. Appendix 2: List of Companies and Organizations

Companies Mentioned

- 4D Molecular Therapeutics

- ACGT

- Advanced BioScience Laboratories

 - Advanced Biotherapeutics Consulting

- Aldevron

- Allele Biotechnology

- Althea Technologies

- Ampersand Capital Partners

- AMSBIO

- Amsterdam BioTherapeutics Unit

- Applied Biological Materials

- Applied Genetic Technologies Corporation

- Applied Viromics

- ARCO Design/Build

- Areta International

- Asklepios BioPharmaceutical

- Atlantic Bio GMP

- Avalanche Biotechnologies

- Batavia Biosciences

- Beckman Research Institute

- Benitec Biopharma

- BioCancell

- Biogen Idec

- Biomay

- Biomiga

- BioReliance/SAFC

- Biotec Services International

- BioTie Therapies

- BioVex (Amgen subsidiary)

- Biovian

- Blue Sky BioServices

- bluebird bio

- BMS

- Boehringer Ingelheim BioXcellence

- Brammer Bio

- Brookside Capital

- Cancer Research UK (Biotherapeutics Development Unit)

- Carnegie Institution of Washington

- Cell and Gene Therapy Catapult

- Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center

- Celladon

- Center for Biomedicine & Genetics, City of Hope

- Center for Cell & Gene Therapy, Baylor College of Medicine

- Center for Cell and Gene Processing, Takara Bio

- Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia

- Centre for Process Innovation

- CEPiA (Industrial Affairs Division of Sanofi )

- CEVEC Pharmaceuticals

- Children's GMP/GMP facility St. Jude Children's Research Hospital

- Cincinnati Children's Hospital Medical Center

- Clinical Biotechnology Centre, NHS Blood and Transplant

- Cobra Biologics

- Core Facility for Therapeutic Vectors, Institute of Medical Science Research Hospital

- Cranfield University

- CRB

- Creative Biogene

- Creed Commercial Development

- Crucell

- CureLab

- Deerfield Management Company

- DSM Biologics

- Epeius Biotechnologies

- EUFETS (BioNTech)

- Eurofins Genomics

- Eurogentec

- Finnish Bioindustries FIB

- Finnish Fair Foundation

- FinVector

- Fondazione Telethon

- Fraunhofer Institute for Toxicology and Experimental Medicine

- Frederik Paulsen Foundation - FUJIFILM Diosynth Biotechnologies

- GEG Tech

- Genable Technologies

- Gene and Cell Therapy Lab, Institute of Translational Health Sciences

- Gene Medicine Japan

- Gene Transfer Vector Core (Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary)

- Gene Transfer, Targeting and Therapeutics Core, Salk Institute for Biological Studies

- Gene Vector and Virus Core, Stanford Medicine

- GeneCure Biotechnologies

- GeneDetect

- GeneImmune Biotechnology

- Genethon (Genethon BioProd)

- GENEWIZ

- GenIbet Biopharmaceuticals

- Génopoïétic

- GenScript

- GenVec

- Genzyme

- GSEx, The Robinson Research Institute, University of Adelaide

- GSK

- Guy's and St Thomas' NHS Foundation Trust

- Hercules Technology Growth Capital

- Hope Center Viral Vectors Core, Washington University School of Medicine

- Human Gene and Cell Therapy Center, Akdeniz University

- Human Stem Cells Institute

- ID Pharma

- Immune Design

- Immune Technology

- Innovate UK

- InvivoGen

- Karolinska University Hospital

- King's College London, Rayne Cell Therapy Suite

- Kobe Biomedical Accelerator

- Lentigen Technology

- Lonza

- Luminous BioSciences

- Massachusetts Eye and Ear

- Massachusetts Life Science Center

- MassBiologics

- Merck

- Meridian Life Science

- MGH Vector Core (Massachusetts General Hospital Neuroscience Center)

- Microbix Biosystems/McMaster University

- Miltenyi Biotec

- Mitsubishi Corporation

- Molecular Diagnostic Services

- MolMed

- Nantes Gene Therapy Institute

- National Institute of Neurodegenerative Disorders and Stroke Center Core

- Nature Technology Corporation

- Netherlands Cancer Institute

- NeuroCure

- Novartis

- Novasep

- Oberland Capital

- Ocular Gene Therapy Core, National Eye Institute

- Okairos (GSK subsidiary)

- Omnia Biologics

- Ospedale San Raffaele

- OXB Solutions

- Oxford BioMedica

- Oxford Genetics

- PacificGMP (a part of Abzena Group)

- Paragon Bioservices

- Penn Vector Core, University of Pennsylvania

- Pfizer

- Pinchal

- Plasmid Factory

- Puresyn

- RecipharmCobra Biologics

- REGENXBIO

- Renova Therapeutics

- Research Center for Hematology of the Russian Ministry of Healthcare

- Richter-Helm

- Rimedion

- Rock Springs Capital

- SAB Technology

- San Raffaele Telethon Institute for Gene Therapy

 - Sanofi

- Sanofi-Pasteur

- Scancell

- Shanghai Sunway Biotech

- Shenzhen SiBiono Gene-Tech

 - SiBionoGeneTech

 - SignaGen Laboratories

- Sino Biological

- Sirion Biotech

- Sofinnova Ventures

- Southern Research

- Bioanalytical Sciences Department

- Spark Therapeutics

- Stanford University (Human Gene Therapy)

- Stevenage Borough Council

- Synpromics

- System Biosciences

- T. Rowe Price Associates

 - Tecrea

- Telethon Foundation

- The Goldyne Savad Institute of Gene Therapy, Hadassah Medical Organization

 - The Hong Kong Institute of Biotechnology

- The Lentiviral Laboratory, USC School of Pharmacy

- The Vector Core, University of North Carolina

 - The Wellcome Trust/BRC Clinical Research Facility and Cell Therapy Unit, King's College London

- THERAVECTYS

- Thermo Fisher Scientific

 - Touchlight Genetics

- Transgene

- UAB Vector Production Facility

- UK Technology Strategy Board

- uniQure

- Unit Biotech & ATMP's, University Medical Center Groningen

- University of Iowa Research Foundation

- University of Massachusetts Medical School

- University of Minnesota - University of North Carolina

 - University of Oxford Clinical BioManufacturing Facility

- University of Pennsylvania - Vaccibody

- Valneva

- Vectalys

- Vector Biolabs

- Vector Core/GMP Core, Belfer Gene Therapy Core Facility, Cornell University

- Vector Core/GMP Facility, UC Davis

- Vector Core Lab/Human Applications Lab, Powell Gene Therapy Center, University of Florida

- Vector Core of Gene Therapy Laboratory of Nantes

- Vector Core, Harvard Gene Therapy Initiative -

 Vector Core, Telethon Institute of Genetics and Medicine

 - Vector Core, University of Michigan Medical Center

- Vector Production Facility, Indiana University

- Vecura

- VGXI

- Vibalogics

- Vical

- ViGene Biosciences

- Viral Gene Transfer Core, MIT

- Viral Vector Core/Clinical Manufacturing Facility, Nationwide Children's Hospital

- Viral Vector Core, Duke University

- Viral Vector Core, Sanford Burnham Prebys Medical Discovery Institute

- Viral Vector Core, University of Massachusetts Medical School

- Viral Vector Core,University of Iowa Carver College of Medicine

- Viral Vector Production Laboratory, Mayo Clinic Cancer Center

- Virovek - VIVEbioTECH

- Voyager Therapeutics

- Waisman Biomanufacturing

- Wellington Management Company

- WH Partnership

- Wolfson Gene Therapy Unit, University College of London

- WuXi AppTec

- ZambonGroup

- Zhengyang Gene Technology

For more information about this report visit http://www.researchandmarkets.com/research/f2hxtm/viral_vectors_and

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.